Management of Actively Bleeding Hemorrhoids on Apixaban

Initial Assessment and Management

The American College of Cardiology recommends classifying bleeding as major or non-major using specific criteria, including bleeding at a critical site, hemodynamic instability, or clinically overt bleeding with hemoglobin decrease ≥2 g/dL or administration of ≥2 units RBCs 1
For patients with non-major hemorrhoidal bleeding on apixaban, the American College of Cardiology recommends continuing apixaban without interruption while implementing local hemostatic measures, such as direct manual compression with gauze 1
The American College of Cardiology suggests using topical hemostatic agents, such as gauze soaked in tranexamic acid, as part of local hemostatic measures 2

For patients with major hemorrhoidal bleeding, the American College of Cardiology recommends stopping apixaban immediately and initiating supportive care, volume resuscitation, and local hemostatic measures 1
The American College of Cardiology suggests administering andexanet alfa if bleeding is life-threatening or uncontrolled, with a low-dose regimen of 400 mg IV bolus followed by 4 mg/min infusion for up to 120 minutes if last apixaban dose ≤5 mg was taken <8 hours prior or timing unknown 3

The American College of Cardiology recommends weighing the risk versus benefit of stopping concomitant antiplatelet agents, such as aspirin or clopidogrel, in patients with major hemorrhoidal bleeding 3

The American College of Cardiology suggests administering prothrombin complex concentrate (PCC) or activated PCC (aPCC) if andexanet alfa is unavailable 3

The American College of Cardiology recommends delaying restarting apixaban if the patient is at high risk of rebleeding or death/disability with rebleeding, or if the source of bleed has not been definitively treated 1
The American College of Cardiology suggests restarting apixaban if the bleeding source has been identified and treated, or if the patient has high thrombotic risk, such as atrial fibrillation with CHA₂DS₂-VASc ≥2, or recent VTE 1, 4

The American College of Cardiology recommends checking serial hemoglobin levels to detect ongoing occult bleeding, and monitoring for signs of recurrent bleeding after initial hemostasis 4